A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

Phase 1 Terminated 24 enrolled AbbVie

RandomizedParallel-groupQuadruple-blindBasic science

Summary

The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability of ABBV-903 or placebo in healthy adult Japanese and Han Chinese subjects.

Timeline

Start: 2023-08-23
Primary completion: 2023-10-30
Completion: 2023-10-30

Outcome

Outcome not reported

Stopped (Business): “Strategic considerations”

Publications

Chowdhury EA, Lee CM, Desai JM, Ali I, Orejudos A, Gupta SV, Ocampo CJ, Miller MG, Jayanth J, Schmidt JM, Salem AH, Mostafa NM. Pharmacokinetic profiling of limnetrelvir in non-Japanese and Japanese populations: results of two phase 1 single- and multiple-dose studies. Antimicrob Agents Chemother. 2026 May 6;70(5):e0144325. doi: 10.1128/aac.01443-25. Epub 2026 Mar 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABBV-903	Unknown	—	Oral

Indications

No indication recorded.